BEVACIZUMAB EFFECT ON TOPOTECAN PHARMACOKINETICS ...

91. Ma, J. and D.J. Waxman, Combination of antiangiogenesis with chemotherapy for
more effective cancer treatment. Mol Cancer Ther, 2008. 7(12): p. 3670-84.
92. Bagri, A., et al., Use of anti-VEGF adjuvant therapy in cancer: challenges and
rationale. Trends Mol Med, 2010. 16(3): p. 122-32.
93. Hicklin, D.J. and L.M. Ellis, Role of the vascular endothelial growth factor
pathway in tumor growth and angiogenesis. J Clin Oncol, 2005. 23(5): p.
1011-27.
94. Kerbel, R.S., Antiangiogenic therapy: a universal chemosensitization strategy for
cancer? Science, 2006. 312(5777): p. 1171-5.
95. Teicher, B.A., A systems approach to cancer therapy. (Antioncogenics + standard
cytotoxics-->mechanism(s) of interaction). Cancer Metastasis Rev, 1996. 15(2): p.
247-72.
96. Miller, K., et al., Paclitaxel plus bevacizumab versus paclitaxel alone for
metastatic breast cancer. N Engl J Med, 2007. 357(26): p. 2666-76.
97. Cao, Y., et al., A meta-analysis of randomized controlled trials comparing
chemotherapy plus bevacizumab with chemotherapy alone in metastatic
colorectal cancer. Int J Colorectal Dis, 2009. 24(6): p. 677-85.
98. Kabbinavar, F., et al., Phase II, randomized trial comparing bevacizumab plus
fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic
colorectal cancer. J Clin Oncol, 2003. 21(1): p. 60-5.
99. Sandler, A., et al., Paclitaxel-carboplatin alone or with bevacizumab for
non-small-cell lung cancer. N Engl J Med, 2006. 355(24): p. 2542-50.
100. Herbst, R.S., et al., Phase II study of efficacy and safety of bevacizumab in
combination with chemotherapy or erlotinib compared with chemotherapy alone
for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol,
2007. 25(30): p. 4743-50.
101. Johnson, D.H., et al., Randomized phase II trial comparing bevacizumab plus
carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously
untreated locally advanced or metastatic non-small-cell lung cancer. J Clin
Oncol, 2004. 22(11): p. 2184-91.
102. Hayes-Jordan, A. and R. Andrassy, Rhabdomyosarcoma in children. Curr Opin
Pediatr, 2009. 21(3): p. 373-8.
103. Paulino, A.C. and M.F. Okcu, Rhabdomyosarcoma. Curr Probl Cancer, 2008.
32(1): p. 7-34.
104. Parham, D.M., Pathologic classification of rhabdomyosarcomas and correlations
with molecular studies. Mod Pathol, 2001. 14(5): p. 506-14.
105. Beverly Raney, R., et al., Results of the Intergroup Rhabdomyosarcoma Study
Group D9602 protocol, using vincristine and dactinomycin with or without
cyclophosphamide and radiation therapy, for newly diagnosed patients with
low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma
Committee of the Children's Oncology Group. J Clin Oncol, 2011. 29(10): p.
1312-8.
106. Chisholm, J.C., et al., Prognostic factors after relapse in nonmetastatic
rhabdomyosarcoma: a nomogram to better define patients who can be salvaged
with further therapy. J Clin Oncol, 2011. 29(10): p. 1319-25.
52